Ginkgo Bioworks Holdings Inc reports results for the quarter ended March 31 - Earnings Summary

Ginkgo Bioworks Holdings

07/05/2025 02:22

Ginkgo Bioworks Holdings Inc DNA.N reported a quarterly adjusted loss of $1.68​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-3.20.  The mean expectation of five analysts for the quarter was for a loss of $1.77 per share. Wall Street expected results to range from $-2.08 to $-1.46 per share.

Revenue rose 27.3% to $48.32 million from a year ago; analysts expected $38.70 million.

Ginkgo Bioworks Holdings Inc's reported EPS for the quarter was a loss of $1.68​.

The company reported a quarterly loss of $90.96 million.

Ginkgo Bioworks Holdings Inc shares had risen by 21.4% this quarter and lost 29.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 17.8% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 4 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "sell"

Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00

This summary was machine generated from LSEG data May 7 at 01:22 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-1.77
-1.68
Beat
Dec. 31 2024
-1.77
-2.00
Missed
Sep. 30 2024
-2.73
-0.94
Beat
Jun. 30 2024
-3.12
-2.80
Beat